Friday, January 20, 2017 3:09:40 PM
All monoclonal antibodies need to come down in price. A combination anti-ctla-4 and anti-pd-1 treatment would likely cost over $250k per patient per year. No company is ever going to achieve significant market share priced like that.
One solution to this problem is to have your body manufacture the antibodies in vivo, either in muscle cells or intratumorally. Both applications should theoretically work. DNA encoded antibodies are reportedly MUCH more scalable and they would require far fewer injections than lab produced mAbs like opdivo, yervoy, keytruda, etc. Improved safety and cost seem like a paradigm shift to me if efficacy is equivalent or better.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM